"Hydroxyapatite-Targeting Nanodrug Halts Aggressive Breast Cancer Growth"
Researchers at Vanderbilt University have developed a nanoparticle-based drug, NSPS, that targets hydroxyapatite (HAP) in tumor microenvironments, causing localized alkalosis and effectively killing cancer cells in animal models of breast, colon, lung, and prostate cancers. The drug shows limited interaction with normal tissue and bone, making it a potential paradigm-changing approach to cancer treatment, particularly for patients with poor prognosis. Further studies in humans are needed to validate its potential clinical impact.